| Project/Area Number |
26462654
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
KUSAKA Shunji 近畿大学, 医学部附属病院, 教授 (60260387)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
國吉 一樹 近畿大学, 医学部, 講師 (30234470)
杉岡 孝二 近畿大学, 医学部, 講師 (50399119)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 未熟児網膜症 / 抗血管内皮増殖因子（VEGF）抗体 / Periostin / 硝子体 / 抗血管内皮増殖因子（VEGF)抗体 / periostin / 抗血管内皮増殖因子(VEGF)抗体 |
|---|
| Outline of Final Research Achievements |
Intravitreal injection of ranibizumab (IVR) was performed in 27 eyes of 14 patients with severe retinopathy of prematurity (ROP). In each eyes, improvement of vascular dilatation and tortuosity, regression of tunica vasculosa lentis, and/or whitening of fibrovascular membranes was observed. Thus, IVR seemed to be effective in reducing disease activity in all eyes. However, reactivation was seen in 7 eyes at 7.3 weeks (mean) after IVR. Suppression of serum vascular endothelial growth factor was observed only at one day, but not 1, 2, and 4 weeks after IVR, compared with that of pre-IVR.
|
